Claritev (NYSE:CTEV – Get Free Report) CEO Travis Dalton bought 4,500 shares of the company’s stock in a transaction on Thursday, August 27th. The shares were acquired at an average price of $38.81 per share, for a total transaction of $174,645.00. Following the transaction, the chief executive officer directly owned 50,372 shares in the company, valued at $1,954,937.32. This trade represents a 9.81% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Travis Dalton also recently made the following trade(s):
- On Friday, August 28th, Travis Dalton bought 1,950 shares of Claritev stock. The shares were acquired at an average cost of $38.48 per share, with a total value of $75,036.00.
Claritev Trading Up 0.7%
Shares of CTEV traded up $0.26 during mid-day trading on Monday, hitting $39.65. The company’s stock had a trading volume of 34,341 shares, compared to its average volume of 161,816. The firm has a 50-day simple moving average of $31.21 and a 200 day simple moving average of $24.74. The firm has a market capitalization of $672.07 million, a P/E ratio of -2.33 and a beta of 0.74. Claritev has a 1-year low of $11.50 and a 1-year high of $74.07.
Hedge Funds Weigh In On Claritev
A number of institutional investors have recently made changes to their positions in CTEV. State of Wyoming acquired a new position in Claritev in the 4th quarter valued at about $25,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Claritev during the third quarter worth about $42,000. Legal & General Group Plc acquired a new position in shares of Claritev in the third quarter valued at approximately $45,000. Los Angeles Capital Management LLC acquired a new position in shares of Claritev in the fourth quarter valued at approximately $45,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Claritev during the third quarter valued at approximately $79,000. 87.15% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of analysts recently commented on CTEV shares. Zacks Research raised shares of Claritev from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Wells Fargo & Company lifted their price target on shares of Claritev from $22.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 12th. Piper Sandler restated an “overweight” rating and issued a $73.00 price target on shares of Claritev in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Claritev in a research note on Wednesday, June 24th. Finally, Citigroup reaffirmed a “buy” rating and set a $45.00 price objective (up from $40.00) on shares of Claritev in a report on Monday, August 10th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $44.83.
Check Out Our Latest Stock Analysis on Claritev
Claritev Company Profile
Claritev is a healthcare technology, data and insights company focused on improving affordability, transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.
Featured Articles
- Five stocks we like better than Claritev
- Don’t Miss These 3 Companies Delivering Strong Guidance Updates
- Insider Confidence Is Building in These 3 Very Different Stocks
- The SaaSpocalypse Trade Is Cracking, and These 5 Stocks Are Leading Higher
- Microsoft’s Split Verdict Tests Investing Without a Fed Safety Net
Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.
